IDEXX Laboratories (IDXX) delivered mixed results in FY2026 on revenue of $104.2B versus the $100.9B estimate (+20.8% YoY) and EPS of $1.89. Below is the full IDEXX Laboratories earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
$104.2B (vs $100.9B est · +3.3% surprise · +20.8% YoY)
EPS
$1.89 (vs $1.97 est · -4.1% surprise · +5.4% YoY)
Share price
$242.32 (+1.4%)
Market cap
$1.06T
What you'll find
Next IDEXX Laboratories (IDXX) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment IDEXX Laboratories reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in IDEXX Laboratories (IDXX)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is IDEXX Laboratories's next earnings date?
IDEXX Laboratories's (IDXX) next scheduled earnings date is Feb 4, 2025. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did IDEXX Laboratories (IDXX) beat or miss earnings?
In FY2026, IDEXX Laboratories (IDXX) posted mixed results — revenue of $104.2B versus the $100.9B estimate (+3.3% surprise) and EPS of $1.89 versus $1.97 expected (-4.1% surprise). Magnisto decodes every IDEXX Laboratories (IDXX) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
What is the forecast for IDEXX Laboratories (IDXX) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for IDEXX Laboratories (IDXX), anchored to the current $242.32 share price, so you can weigh the bull, base and bear cases for IDEXX Laboratories side by side.
Is IDEXX Laboratories (IDXX) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether IDEXX Laboratories fits your own thesis and risk profile. This is research, not investment advice.